Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 37.00 | |
5 mg | In stock | $ 87.00 | |
10 mg | In stock | $ 117.00 | |
25 mg | In stock | $ 223.00 | |
50 mg | In stock | $ 393.00 | |
100 mg | In stock | $ 585.00 | |
500 mg | In stock | $ 1,270.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 91.00 |
Description | Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM. |
Targets&IC50 | JAK2:6 nM, JAK1:12 nM, Tyk2:0.5 nM, JAK3:8 nM, Syk:32 nM |
In vitro | In human whole blood from normal donors, Cerdulatinib affects BCR-mediated B-cell activation by dual inhibition of SYK and JAK. As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduces cell viability in a subset of NHL cell lines, and induces apoptosis in BCR-signaling competent NHL cell lines. [1] |
In vivo | In a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg p.o.) significantly improves inflammatory infiltrate within the synovium and the integrity of the articular cartilage. In addition, Cerdulatinib also blocks BCR-induced B-cell activation and splenomegaly in mice. [1] |
Kinase Assay | Purified Kinase Assays: Potency against purified SYK is determined by fluorescence resonance energy transfer. A broader panel of 270 purified kinases is surveyed in which PRT062070 is tested at a fixed concentration of 300 nM. [33P]-labeled substrate is measured after incubation of purified kinase with peptide substrate and [33P]ATP at the Km concentration for the kinase. |
Cell Research | Cell lines (Ramos RA-1, Daudi, Toledo, SU-DHL4 and SU-DHL6) are cultured in RPMI media supplemented with 10% fetal bovine serum. Cells are treated with the indicated concentrations of PRT062070, the SYK-selective inhibitor PRT060318, the pan-JAK inhibitor 1, a 1:1 combination of PRT060318 and JAK inhibitor 1, or vehicle control (0.5% dimethylsulfoxide) for 72 hours. Cell viability assays are performed using CellTiter Glo in 384-well plates. Cells are seeded at a density of 5000 cells per well. (Only for Reference) |
Synonyms | PRT062070 hydrochloride, Cerdulatinib, PRT2070, PRT062070, PRT2070 hydrochloride |
Molecular Weight | 482 |
Formula | C20H28ClN7O3S |
CAS No. | 1369761-01-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
H2O: <1 mg/mL
Ethanol: <1 mg/mL
DMSO: 40 mg/mL (83 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cerdulatinib hydrochloride 1369761-01-2 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling MAPK Stem Cells Tyrosine Kinase/Adaptors Syk JAK MLK c-Fms Hippo pathway Tyrosine Kinases PRT062070 hydrochloride PRT 062070 PRT 2070 Inhibitor Cerdulatinib PRT2070 malignancies Tyk2 PRT-062070 PRT062070 Janus kinase PRT-2070 PRT2070 hydrochloride autoimmune dual B-cell Spleen tyrosine kinase inhibit inhibitor